Deutsche Märkte öffnen in 6 Stunden 53 Minuten

Sonoma Pharmaceuticals, Inc. (SNOA)

NasdaqCM - NasdaqCM Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
0,4230+0,1150 (+37,34%)
Börsenschluss: 04:00PM EDT
0,4012 -0,02 (-5,15%)
Nachbörse: 07:47PM EDT

Sonoma Pharmaceuticals, Inc.

5445 Conestoga Court
Suite 150
Boulder, CO 80301
United States
800 759 9305
https://sonomapharma.com

Sektor(en)Healthcare
BrancheDrug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter10

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Ms. Amy M. TromblyCEO, President & Director608,82kN/A1968
Mr. Jerome J. DvonchChief Financial Officer268,79kN/A1968
Mr. Bruce ThorntonExecutive VP, COO & Corporate Secretary540,94kN/A1964
Mr. John Dal PoggettoController433,36kN/A1972
Die Beträge haben den Stand 31. Dezember 2024 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Corporate Governance

Sonoma Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.